Human Metabolome Technologies Balance Sheet Health
Financial Health criteria checks 5/6
Human Metabolome Technologies has a total shareholder equity of ¥1.8B and total debt of ¥200.0M, which brings its debt-to-equity ratio to 11%. Its total assets and total liabilities are ¥2.3B and ¥480.0M respectively. Human Metabolome Technologies's EBIT is ¥245.0M making its interest coverage ratio 122.5. It has cash and short-term investments of ¥1.5B.
Key information
11.0%
Debt to equity ratio
JP¥200.00m
Debt
| Interest coverage ratio | 122.5x |
| Cash | JP¥1.46b |
| Equity | JP¥1.81b |
| Total liabilities | JP¥480.00m |
| Total assets | JP¥2.29b |
Recent financial health updates
Recent updates
Human Metabolome Technologies' (TSE:6090) Weak Earnings May Only Reveal A Part Of The Whole Picture
Oct 03
Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The Market
Aug 06Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00
Jun 07Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00
May 22Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year
Apr 06Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00
Mar 23Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00
Feb 26Financial Position Analysis
Short Term Liabilities: 6090's short term assets (¥1.8B) exceed its short term liabilities (¥458.0M).
Long Term Liabilities: 6090's short term assets (¥1.8B) exceed its long term liabilities (¥22.0M).
Debt to Equity History and Analysis
Debt Level: 6090 has more cash than its total debt.
Reducing Debt: 6090's debt to equity ratio has increased from 0% to 11% over the past 5 years.
Debt Coverage: 6090's debt is well covered by operating cash flow (118%).
Interest Coverage: 6090's interest payments on its debt are well covered by EBIT (122.5x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 18:15 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Human Metabolome Technologies, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |